SRR934897
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.597
- INTERFERON_ALPHA_RESPONSE+0.577
- ANGIOGENESIS+0.574
- ALLOGRAFT_REJECTION+0.555
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.552
- IL6_JAK_STAT3_SIGNALING+0.552
- INFLAMMATORY_RESPONSE+0.540
- TNFA_SIGNALING_VIA_NFKB+0.489
- APOPTOSIS+0.486
- COMPLEMENT+0.475
Top 10 suppressed
- KRAS_SIGNALING_DN-0.462
- SPERMATOGENESIS-0.316
- PANCREAS_BETA_CELLS-0.279
- HEDGEHOG_SIGNALING-0.127
- MYOGENESIS-0.069
- ESTROGEN_RESPONSE_EARLY+0.007
- WNT_BETA_CATENIN_SIGNALING+0.027
- ESTROGEN_RESPONSE_LATE+0.048
- HEME_METABOLISM+0.071
- UV_RESPONSE_UP+0.104
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934913 | — | — | 0.974 |
| 2 | DD203D19-D635-4112-AF75-9724E0A64A0B | — | — | 0.974 |
| 3 | 0E5EDC5A-5AD4-499E-8777-CA6B6F63307F | — | — | 0.971 |
| 4 | SRR934921 | — | — | 0.971 |
| 5 | C13F6AB6-41C0-4F51-A240-BA4F4410B68E | — | — | 0.969 |
| 6 | B7A23896-4182-48D3-A1D9-92C781BF283F | — | — | 0.968 |
| 7 | SRR934750 | — | — | 0.968 |
| 8 | F9EB85A8-8E6D-44C0-8C59-50B1DB4E652B | — | — | 0.966 |
| 9 | A219A5D7-C67B-4CF0-860A-78ADEB56A13D | — | — | 0.965 |
| 10 | 825AC0F8-4D16-4109-AA6A-4648934E3C35 | — | — | 0.964 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.597 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.577 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.574 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.555 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.552 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.552 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.540 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.489 | Inavolisib | — uncovered |
| APOPTOSIS | 0.486 | Idelalisib | — uncovered |
| COMPLEMENT | 0.475 | Inavolisib | — uncovered |
| COAGULATION | 0.459 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.447 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.445 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.437 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.415 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.401 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.399 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.386 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.384 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.378 | Inavolisib | — uncovered |